1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends

EpiCast Report: Colorectal Cancer - Epidemiology Forecast to 2025

  • December 2016
  • 55 pages
  • GlobalData
Report ID: 2522994

Summary

Table of Contents

Search Inside

EpiCast Report: Colorectal Cancer - Epidemiology Forecast to 2025

Summary

Colorectal cancer (CRC) is a cancer that starts in the colon or the rectum (ACS, 2016). CRC is one of the most common types of cancers diagnosed; it is the third most common cancer among men and the second most common in women, worldwide (Ferlay et al., 2016). CRC is a high-mortality cancer, with mortality rates just behind lung, liver, and stomach cancers in men, and breast and lung cancers in women.

In 2015, there were 746,590 diagnosed incident cases of CRC in the 8MM. Epidemiologists forecast that the diagnosed incident cases in the 8MM will increase to 913,832 by 2025 at an Annual Growth Rate (AGR) of 2.24%. With the exception of the US and Germany, all markets will see an increase in the number of cases, at varying AGRs. The 8MM combined had an estimated 2,582,288 five-year diagnosed prevalent cases of CRC in 2015. The number of five-year diagnosed prevalent cases will increase by 22.06% over the next 10 years to 3,151,930 by 2025.

Urban China will have the highest number of diagnosed incident and five-year diagnosed prevalent cases among the 8MM, as well as the highest AGR for both data types. The US and Germany are the only markets that will see a decrease in incidence rate during the forecast period.

Worldwide, CRC is the third most common cancer in men and the second most common cancer in women (Ferlay et al., 2016). Estimates show that almost 55% of CRC cases are diagnosed in more developed regions (Ferlay et al., 2016). CRC has a strong relationship with age, and it is most commonly diagnosed in patients older than 65 years (Erichsen et al., 2013; Jørgensen et al., 2012). In 2012, CRC accounted for almost 10% of the global cancer incidence burden (Stewart and Wild, 2014). A study examining the global trends of CRC analyzed data from 51 cancer registries around the world and found that incidence of CRC increased significantly in countries going through an economic transition such as those found in Eastern Europe, most parts of Asia, and certain parts of South America (Center et al., 2009b).

The report “EpiCast Report: Colorectal Cancer - Epidemiology Forecast to 2025” provide an overview of the risk factors and global trends of CRC in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and China [urban]). It includes a 10-year epidemiological forecast of the diagnosed incident cases and the five-year diagnosed prevalent cases of CRC in these markets from 2015–2025.

Scope

- The Colorectal Cancer (CRC) EpiCast Report provides an overview of the risk factors and global trends of CRC in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and China [urban]). It includes a 10-year epidemiological forecast of the diagnosed incident cases and the five-year diagnosed prevalent cases of CRC in these markets from 2015-2025. The diagnosed incident cases of CRC are further segmented by age, sex, stage at diagnosis, and genetic mutations.
- The CRC epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

The CRC EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global CRC market.
- Quantify patient populations in the global CRC market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CRC therapeutics in each of the markets covered.
- Compare patient population potentials by genetic mutation and stage at diagnosis.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Epiomic Epidemiology Series: BRCA 1 & 2 Mutation in Cancer Forecast in 18 Major Markets 2017-2027

  • $ 6859
  • Industry report
  • June 2017
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on BRCA1 and BRCA2 mutation in Cancer in 18 Major Markets It has long been established that BRCA1 and BRCA2 (BReast CAncer susceptibility ...

Epiomic Epidemiology Series: PD-L1 Overexpression in Solid Tumours Forecast in 18 Major Markets 2017-2027

  • $ 6859
  • Industry report
  • June 2017
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on PDL-1 over-expression in Cancer in 18 Major Markets PD-1 is a T-cell immune checkpoint that is involved in the dampening of autoimmunity ...

Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market

  • $ 4995
  • Industry report
  • July 2017
  • by GBI Research

Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market Summary Colorectal cancer (CRC) originates in eithe ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.